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Abstract: Nuclear spin polarization can be significantly increased 
through the process of hyperpolarization, leading to an increase in 
the sensitivity of nuclear magnetic resonance (NMR) experiments by 
4–8 orders of magnitude. Hyperpolarized gases, unlike liquids and 
solids, can be more readily separated and purified from the 
compounds used to mediate the hyperpolarization processes. These 
pure hyperpolarized gases enabled many novel MRI applications 
including the visualization of void spaces, imaging of lung function, 
and remote detection. Additionally, hyperpolarized gases can be 
dissolved in liquids and can be used as sensitive molecular probes 
and reporters. This mini-review covers the fundamentals of the 
preparation of hyperpolarized gases and focuses on selected 
applications of interest to biomedicine and materials science. 
1. Introduction 
The use of techniques to enhance nuclear spin polarization (P) 
to order unity (i.e. nearly 100%) results in corresponding gains in 
NMR sensitivity by 4-8 orders of magnitude.[1] This process of 
significant polarization enhancement—well above that achieved 
at thermal equilibrium—is termed hyperpolarization. 
Hyperpolarization of solids, liquids, and gases[2] has been 
demonstrated via a number of techniques including Brute Force 
Polarization (BFP),[3] Spin Exchange Optical Pumping (SEOP),[4] 
Dynamic Nuclear Polarization (DNP),[1c] Chemically-Induced 
Dynamic Nuclear Polarization (CIDNP)[5] photo-CIDNP,[6] 
Parahydrogen Induced Polarization (PHIP),[7] and Signal 
Amplification By Reversible Exchange (SABRE).[8]. A wide range 
of nuclei can be directly hyperpolarized, including 1H,[9] 3He,[10] 
7Li[11], 13C,[1c, 12] 15N,[13] 19F,[14] 31P,[15] 83Kr,[16] and 129Xe,[4, 17] 
among others.[18] Hyperpolarized (HP) substances are 
revolutionizing the fields of NMR spectroscopy and magnetic 
resonance imaging (MRI), because many applications that were 
previously impractical because of weak NMR signals (e.g. 
metabolites at sub-mM) are now becoming possible. Moreover, 
the enormous gain in attainable SNR allows spectroscopic 
detection and imaging of HP compounds to be performed in 
seconds, obviating the need for time-consuming signal 
averaging and thermal recovery of the spin magnetization. The 
ability to rapidly acquire signals with very high SNR from HP 
systems is the inherent feature that is greatly desirable for in 
vivo gas imaging applications: i.e. images can be acquired 
during a single breath hold; sufficient signal can be attained 
despite low density of gas compared to liquid. While liquid HP 
contrast agents are injected in vivo to probe metabolism[19] 
(extensively discussed in many recent reviews)[20] or used 
otherwise,[21] they typically cannot be used to probe gas-phase 
processes in vitro or in vivo. This mini-review focuses on the 
techniques allowing the production of HP gases with particular 
application to their use in biomedical applications, and explores 
some examples from materials science. 
We begin with the fundamentals of SEOP in the context of 
NMR hyperpolarization of 129Xe gas. Although other noble gases 
have been hyperpolarized, none are as widely used for magnetic 
resonance as HP 129Xe, which has a relatively large natural 
abundance (ca. 26%) and is relatively cheap (ca. $20/L). The 
selected applications described here include functional lung 
imaging,[22] metabolic brown fat imaging,[23] and biosensors[24] 
(including those enabled by genetic encoding[25]). A recent 
demonstration of the DNP process to hyperpolarize 129Xe[26] and 
hydrocarbon gases[27] is also described. 
HP gases can also be efficiently produced via PHIP, when 
parahydrogen gas is added in a pairwise manner to a multiple 
chemical bond (C=C or CC) in an unsaturated molecule—
resulting in a gaseous HP product. This process can be 
performed in heterogeneous fashion,[9a, 28] and despite low T1 of 
the HP states, this powerful scalable technique allows for cheap 
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preparation of HP hydrocarbons on demand. Moreover, because 
protons are being directly hyperpolarized and detected, it is 
inexpensive and straightforward to perform (since expensive 
isotopic enrichment and heteroatoms-specific instrumentation 
can be obviated) and thus is readily applied with conventional 
clinical MRI scanners. This mini-review describes the 
fundamentals of PHIP for production of HP gases,[29] selected 
recent developments to extend the lifetime of the HP state 
through the use of the long-lived spin states (LLSS),[30] and HP 
gas application for void space imaging, remote sensing, time of 
flight imaging, and micro-fluidic imaging. 
In all cases, the separation from other compounds required 
for hyperpolarization process (e.g. Rb in case of SEOP of HP 
129Xe, un-paired radicals in the case of DNP, and homogeneous 
or heterogeneous catalysts in the case of PHIP) is well known, 
and experiments can be performed with HP gases in a 
chemically pure form. 
2. Fundamentals of Noble Gas 
Hyperpolarization 
2.1. SEOP 
The most commonly employed method for generating HP noble 
gases is spin-exchange optical pumping (SEOP). The 
development of SEOP is rooted in the pioneering work of 
Kastler,[31] who was recognized with the Nobel Prize in physics 
for demonstrating that electronic spin order can be created in 
alkali metal vapors using circularly polarized laser light. Later 
Bouchiat, Carver, and Varnum[32] showed that the addition of 
3He to the gas mixture permitted helium nuclear spins to be 
polarized by spin-exchange collisions with the optically pumped 
alkali vapor atoms—work that was extended to 129Xe by 
Grover.[33] The rich physics of SEOP has been extensively 
explored by Happer, Cates, Chupp, Walker, and many others 
(e.g. Refs. [4, 17b, 34]), ultimately leading to the ability to produce 
large quantities of HP noble gases with nuclear spin polarization 
levels approaching unity for use in a variety of applications—
including those described throughout this Mini-Review. 
The underlying phenomenon of SEOP has been reviewed 
extensively elsewhere,[4, 35] but can be briefly described as 
follows (Figure 1): First, a heated alkali metal vapor is irradiated 
with resonant circularly polarized light. Angular momentum 
conservation results in population being driven from appropriate 
spin-state ground states (e.g. mJ=-1/2 with + light, neglecting 
nuclear spin degrees of freedom). The ground state levels are 
repopulated at roughly the same rates, resulting in depletion of 
one spin state and population accumulation in the other—
rendering the alkali metal vapor electronically spin polarized. 
Gas-phase collisions then transfer polarization from the 
electrons of the alkali metal to the spins of the noble gas nuclei 
via Fermi-contact interactions. This process is allowed to 
continue so that the nuclear spin polarization can accumulate 
over time, ultimately yielding a steady-state nuclear spin 
polarization given by: 
𝑃N = 〈𝑃AM〉 ⋅ (
𝛾SE
𝛾SE + 𝛤𝑁
) 
where 〈𝑃AM〉 is the spatially averaged polarization of the alkali 
metal vapor, N is the noble gas nuclear longitudinal relaxation 
rate (1/T1) in the optical pumping cell, and SE is the spin-
exchange rate (i.e., the rate at which polarization can be 
transferred from alkali metal to the noble gas). 
 
Figure 1. Schematic representations of SEOP.[2b, 4] (a) SEOP cell containing a 
noble gas (here, Xe), buffer gases (e.g. N2), and a small quantity of vaporized 
alkali metal (here, Rb); the cell is irradiated by circularly polarized laser light 
that can be absorbed by the alkali metal atoms. (b) The first step of SEOP: in 
order to conserve angular momentum, photon absorption results in selective 
population depletion from one Rb ground electronic state (neglecting Rb 
nuclear spin for simplicity). Although gas-phase collisions work to equalize the 
excited-state populations (and hence, the ground-state repopulation rates), 
continuous depletion of one state by the laser leaves the AM vapor 
electronically spin-polarized. (c) The second step of SEOP: Gas-phase 
collisions occasionally allow spin order to be transferred from the AM atom 
electrons to the noble gas nuclei via Fermi contact hyperfine interactions, 
thereby hyperpolarizing the noble gas over time. Reproduced with permission 
from Ref. [2b] © John Wiley & Sons, Ltd., 2015. 
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Although the vast majority of SEOP experiments have employed 
the spin I=1/2 noble gas isotopes 129Xe and 3He, the quadrupolar 
species 21Ne (I=3/2),[36] 83Kr (I=9/2),[37] and 131Xe[38] (I=3/2) can 
also be polarized via this method.  For the alkali metal vapor, Rb 
is most-commonly employed for practical reasons—including its 
low melting point[39] (facilitating vaporization) and the availability 
of high-powered lasers resonant with its D1 transition[40]; 
however, K and Cs are also utilized (particularly for 3He[41] and 
129Xe,[42] respectively). 
Technological developments for SEOP have been 
extensively reviewed elsewhere,[35] and only a brief description is 
given here. Devices for preparing HP noble gases may be 
grouped into two types: “stopped-flow” and “continuous-flow”. In 
a stopped-flow device,[43] a batch of a desired gas mixture is 
loaded into an OP cell (which contains a quantity of AM) and is 
heated and optically pumped with a laser; once the gas is 
hyperpolarized, OP is stopped and the gas is transferred to the 
sample (usually after the cell has cooled to condense the AM); 
alternatively, multiple batches may be systematically polarized 
and collected to accumulate the HP gas prior to transfer. In a 
continuous-flow device,[44] a desired gas mixture is allowed to 
flow from its source continuously through a heated cell while it is 
irradiated by the laser; the flow rate is chosen to allow sufficient 
average residency of noble gas atoms in the cell to enable the 
gas to be hyperpolarized “on the fly”. The HP gas mixture can 
then either be directed into the sample or a cryo-condenser (to 
collect the otherwise-dilute HP noble gas and deliver it purely 
and with high density, following sublimation[44a]). 
All of the noble gas isotopes are amenable to the stopped-
flow design[38, 43h, i, 45], whereas the relatively high spin-exchange 
rates and facile cryo-storage of 129Xe’s polarization[46] make it the 
best choice for use in a continuous-flow device.  Both device 
designs have evolved considerably over the years, achieving 
ever-greater gas polarizations and production 
amounts/throughputs—benefiting in particular from the advent of 
compact, high-power, relatively low-cost light sources embodied 
by spectrally-narrowed laser diode arrays.[40, 43e, g, 44f, 47] 
2.2. Other Methods for Hyperpolarizing Noble gases: MEOP, 
“Brute Force”, and DNP 
In addition to SEOP, HP noble gases can be prepared by 
metastability exchange optical pumping (MEOP), “brute force”, 
and dynamic nuclear polarization (DNP), and we briefly describe 
these approaches here. 
In MEOP,[48] an electrical discharge is used to create 
metastable (electronically excited) atoms in a dilute gas.  The 
unpaired electrons of these metastable atoms can be spin-
polarized via optical pumping with a laser. The angular 
momentum of the electron spin may then be transferred to the 
nuclear spin of another gas atom in the cell during a 
metastability-exchange collision. The process is allowed to 
continue until a bulk nuclear spin polarization develops across 
the cell. Finally, a pump is used to compress the HP gas to a 
sufficient density prior to use.[49] MEOP works well for 3He[48] and 
has been highly effective at producing clinical-scale amounts for 
biomedical imaging experiments (e.g. [50]); MEOP is generally 
less effective for the heavier noble gas isotopes because of 
stronger relaxation mechanisms.[51] 
Next, to understand the so-called brute-force (BF) approach, 
one should first consider the relation determining the equilibrium 
(“thermal”) nuclear spin polarization (for I=1/2 nuclei): 
𝑃N
eq
≐ tanh(
γℏ𝐵0
2kT
), 
where 𝛾  is the nuclear gyromagnetic ratio, 𝐵0  quantifies the 
strength of the magnetic field, 𝑇 is the absolute temperature, ℏ is 
Planck’s constant divided by 2 and k is Boltzmann’s constant. 
At room temperature and in a typical superconducting magnet, 
𝑃𝑁
𝑒𝑞
 will be ~10-5-10-6. Thus, if the sample temperature were 
lowered to milli-Kelvin temperatures (and enough time were 
allowed for the nuclear spins to relax to their new equilibrium 
conditions), the nuclear spin polarization would exceed 10%. 
Although the approach can be time consuming, such BF 
approaches have used 3He/4He dilution refrigerators to polarize 
the nuclear spins in different substances, including noble 
gases.[52] 
Finally, noble gases can also be hyperpolarized via DNP.[53] 
Here, the approach is essentially the same as that of dissolution 
DNP (d-DNP), introduced by Golman and co-workers in 2003.[1c] 
Briefly, the approach requires the substance to be 
hyperpolarized (here, 129Xe) to be mixed in a glassy frozen 
matrix containing molecules with unpaired electron spins (e.g., a 
stable radical or a photoinduced, non-persistent radical[53c]). With 
the matrix placed at very low temperatures (~1 K) and at high 
magnetic field (several T), the unpaired electrons obtain a near-
unity spin polarization. The matrix is then irradiated with 
microwaves in order to drive the high spin polarization to 
surrounding nuclei in the matrix, allowing a high bulk nuclear 
spin polarization to accumulate over time. The matrix is then 
rapidly warmed, sublimating the HP xenon as a pure gas—
hence the name “sublimation DNP” given for this approach.[53b] 
Using DNP, polarization values of ~30% have been achieved in 
~1.5 hr,[53b] despite identified issues with a spin-diffusion 
bottleneck between electron and 129Xe spins.[53a] Although the 
amounts and polarization values achieved thus far with DNP are 
not as high as corresponding values achieved with SEOP, the 
advantages are the increasing availability and general 
applicability of dissolution DNP polarizers in biomedical 
facilities—including Oxford’s HyperSense[1c] and more recently, 
GE Healthcare’s SPINlab.[54] 
2.3. The Rise of Magnetic Resonance Applications of 
Hyperpolarized Noble Gases 
Prior to finding their way into magnetic resonance, HP gases 
found their first applications in fundamental physics experiments 
(work that of course continues, see for example, Refs. [55],[56]). 
And although the portions of this Mini-Review that are dedicated 
to HP noble gases are largely concerned with biomedical 
applications of 129Xe, the first MR applications actually involved 
studies of materials (as well as investigations of the use of HP 
129Xe as a source of hyperpolarization for other spins). 
Soon after the demonstration of ultra-long 129Xe relaxation times 
for frozen solid xenon,[46] Pines and co-workers used HP 129Xe 
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NMR to probe the surfaces of powdered substances[43a] (and 
high-field gas-phase spectroscopy was also demonstrated by 
performing SEOP within an NMR magnet[42a]). Soon afterwards, 
the exquisite sensitivity of the 129Xe chemical shift was 
investigated for probing surfaces of a number of porous 
materials and particles[57]—as was the ability to transfer the 
129Xe hyperpolarization to the nuclear spins of other 
substances.[58] The advent of continuous-flow production of HP 
129Xe[44a] was soon applied to greatly facilitate studies of 
materials surfaces,[59] including under conditions of magic angle 
spinning.[60] Since that work, HP xenon has been used to study 
diffusion in confined spaces or porous media[61],[62],[63]; image 
such systems as a function of gas flow[64] or 129Xe chemical 
shift[65]; or spectroscopically probe single-crystal surfaces[66], 
liquid crystals,[67] or combustion processes.[68] However, the 
greatest body of materials-related work has concerned the effort 
to probe void spaces and surfaces in microporous or 
nanoporous materials with HP 129Xe, thereby providing 
information about pore size, pore shape, and gas dynamics in: 
nanochanneled organic, organometallic, and peptide-based 
molecular materials[69] (including in macroscopically oriented 
single crystals[70]); multi-walled carbon nanotubes[71]; gas hydrate 
clathrates[72]; porous polymeric materials and aerogels[73]; metal-
organic frameworks[74]; calixarene-based materials and 
nanoparticles[75]; organo-clays[76]; mesoporous silicas[77]; and 
zeolites and related materials[78] — efforts that have been aided 
by computational studies of xenon in confined spaces (e.g., Refs. 
[79]). For a more in-depth review of HP 129Xe in microporous and 
nanoporous materials, see Ref. [80]. 
Indeed, 129Xe has found the widest NMR/MRI application of 
the HP noble gases—a fact that is at least partially due to its 
significant natural abundance (26.44%) and ready recoverability 
from air during oxygen production. While 3He does have the 
advantage of a roughly three-fold greater gyromagnetic ratio, its 
weak chemical shift dependence and lack of significant 
interaction with other substances make it a poor probe of other 
substances. More importantly, the lack of natural abundance 
(most 3He comes from tritium decay) will limit the future use of 
this isotope for wide-scale magnetic resonance applications.[81] 
The rapid relaxation suffered by the quadrupolar isotopes (21Ne, 
83Kr, and 131Xe) presents a challenge for most HP NMR 
applications, although as pointed out by Meersmann and co-
workers, the quadrupolar interaction also endows a unique 
sensitivity of HP 83Kr to surface chemistry and local geometry 
that can be complementary to the information provided by 129Xe 
chemical shift – a feature that can prove useful for probing 
porous materials, lung tissues, and other systems.[37, 68b, 82] 
3. Clinical Application of Hyperpolarized 
Xenon-129 MRI 
HP xenon-129 MRI (129Xe-MRI) is an MRI modality first 
developed in 1990s for enhanced lung imaging of ventilation and 
perfusion and regional information on gas exchange. It has been 
used to image patients with a number of respiratory diseases, 
including asthma, COPD, and pulmonary fibrosis. In addition to 
its use in disease assessment and long-term management, in 
vivo gas-phase 129Xe-MRI has the potential to provide imaging 
biomarkers of drug efficacy, which could be used to stratify 
treatment, improve patients’ quality of life, and cut down 
healthcare costs. It can also be potentially employed by 
pharmaceutical companies to speed up decision-making in 
proof-of-concept studies in drug development. 
3.1. From Mice to Men 
Identified by British chemists William Ramsay and Morris 
Travers in 1898[83] (following their discovery of neon and krypton 
a few months beforehand), xenon is a colorless and odorless 
noble gas. Xenon initially captured the attention of clinicians as a 
general anesthetic agent when Albert Behnke, a US Navy 
physician, investigated the cause for ‘drunkenness’ observed in 
deep-sea divers.[84] Interestingly, Behnke also happened to be 
the clinician who had studied the anesthetic effects of nitrogen 
and helium in humans.[85] It was Lawrence et al.,[85] who first 
published experimental data on the general anesthetic effects of 
xenon with mice as their test subjects. It took clinicians 5 years 
to put xenon to use in clinical settings,[86] and xenon has 
continued to be used as a general anesthetic since. 
3.2. The Motivation for Hyperpolarized Xenon-129 MRI 
The next major clinical application of xenon-129 came in 1994 in 
the form of its use as an inhalational contrast agent for magnetic 
resonance imaging (MRI).[87] 
Plain radiograph and computed tomography (CT) are 
currently the main modalities used to image the lungs in clinical 
settings. Despite their ability to provide detailed anatomical data, 
in particular with high resolution CT, their main drawbacks are 
the risks involved with repeated radiation exposure and the 
inability to provide physiological information on regional lung 
function. Although conventional MRI has been a game-changer 
in both neuro and hepatic imaging, its dependence on the 
protons of water molecules in tissue to provide nuclear magnetic 
resonance (NMR) signal[87] has meant that it is of little value in 
imaging the lungs due to poor image quality because of three 
factors: 1- low proton abundance within the lung parenchyma, 2- 
air-tissue interface causing magnetic field heterogeneity, and 3- 
image degradation secondary to cardiac and respiratory 
motion.[88] 
The NMR signal strength of a given species depends on its 
nuclear spin, i.e. polarization, and the volume of the element. 
Except for those in water and fat, the concentrations of all other 
protons and nuclear species are too low to be of use in 
conventional MRI. However, hyperpolarization can be used to 
overcome the otherwise low detection sensitivity for low-
concentration spins. For example, by delivering HP 129Xe to 
excised mouse lungs, Albert and colleagues were able to obtain 
improved MR lung images compared to those obtained with 
conventional MRI.[87] 
3.3. Hyperpolarized Xenon-129 MRI — There and Back Again 
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HP xenon-129 MRI of human lungs, which are obviously much 
larger than those of mice, proved challenging; it took physicists 
three years following Albert’s paper in 1994 to be able to publish 
data on human studies.[89] The challenge was due to the need to 
produce much larger quantities of HP 129Xe and to achieve 
adequate levels of polarization. Furthermore, conventional MR 
imaging sequences had to be modified as the polarization of the 
noble gas is non-renewable, and some polarization is lost every 
time an MR excitation pulse is applied.[90] These issues led to a 
shift in interest from 129Xe to helium-3 (3He), a fellow noble gas, 
whose larger gyromagnetic ratio and larger achievable 
polarization compared to 129Xe at the time allowed for better 
signal intensity and image resolution for a given amount of HP 
gas.[91] 
Interest in 129Xe was reignited in the early 2010s; this 
resurgence was due to the fact that contrary to 129Xe, which is 
naturally occurring, 3He is a byproduct of tritium decay. 3He had 
become scarce as the US sequestered 3He for 3He-based 
neutron detectors for national security, leading to extremely low 
availability of 3He for scientific research and an exponential rise 
in its price.[91b] As a result, it was unlikely that 3He-MRI would 
become a routine imaging modality in clinical settings, and so 
interest in 129Xe-MRI was rekindled. 
3.4. Safety & Tolerability Profile in Patient Groups 
Over the past two decades, 129Xe-MRI has been improved and 
utilized in imaging a wide range of respiratory diseases, 
including asthma,[92] chronic obstructive pulmonary disease 
(COPD),[92b, 93] cystic fibrosis (CF),[92a] and pulmonary fibrosis.[94] 
Studies specifically designed to investigate the safety and 
tolerability of 129Xe-MRI have not shown major common side 
effects in various patient groups, including those with asthma,[92a] 
and mild-moderate COPD,[92a, 95] with light-headedness of very 
short duration as the main reported minor side effect. 
3.5. Ventilation Imaging 
Ventilation imaging provides valuable clinically relevant 
information relevant to regional lung function. Regions with 
normal ventilation typically appear bright and homogenous on 
129Xe-MRI, and in a healthy subject with normal lung function, 
both lungs show relatively homogenous ventilation except for 
two regions (as seen in Figure 2 and discussed in Figure 2 
caption). In those with diseased lungs where regional ventilation 
is impaired, the abnormal regions will appear darker; these 
regions are called ‘ventilation defects’. 
Compared to healthy volunteers, 129Xe distribution has been 
shown to be regionally heterogeneous with ventilation defects in 
a number of different patient groups, including those with 
asthma, COPD, and CF.[92a, 93c, d] Ventilation imaging has also 
been shown to correlate with spirometry [93c] and CT findings [96] 
in patients with COPD. 
Additionally, ventilation imaging has been used to try and 
assess the efficacy of drug therapy. Studying the impact of 
salbutamol in patients with asthma, Parragra’s group [92b] has 
reported a significant reduction in ventilation defects after 
salbutamol administration. 
Hence 129Xe-MR ventilation imaging, although appearing 
simple, can be used to not only assess disease, but to also 
assess drug efficacy and monitor disease progression. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 129Xe-MRI of a healthy volunteer. a) Coronal plane 25 mm slice 
129Xe-MR ventilation image of a healthy adult male, with 129Xe appearing bright. 
The upper airways are delineated. b) Coronal plane 25 mm slice fused 129Xe-
MR ventilation and proton co-registration image, with 129Xe appearing green. 
The two black regions pointed out in the fused image (yellow arrows) are due 
to a diaphragmatic eventration and pulmonary vasculature, clearly defined on 
the fused image (blue arrows). J. Thorpe, B. Haywood, M. Barlow, S. Safavi & 
I. Hall - University of Nottingham (Unpublished work). 
3.6. Diffusion Imaging 
The apparent diffusion coefficient (ADC) of gas within lung is a 
function of alveolar size and geometry.  This can be assessed 
using 129Xe-MRI to characterize pulmonary microstructure at the 
alveolar level, as seen in Figure 3. 
 
 
 
 
 
 
 
 
 
 
Figure 3. ADC map of a healthy volunteer and a patient with COPD.  a) 
Healthy volunteer with a low mean ADC of 0.037±0.021 cm2/s, indicating 
normal alveolar microstructure. b) Patient with COPD with high ADC values 
(0.068±0.028 cm2/s) in the parenchyma, indicating alveolar destruction. 
Reproduced with permission from Ref. [95] © John Wiley & Sons, Ltd., 2011. 
 
129Xe-MRI derived ADC mapping has been shown to 
correlate well with pulmonary function tests,[93d, 95] including total 
diffusing capacity for the lung (TLco). This is of important clinical 
significance, as it clearly illustrates the ability of 129Xe-MRI to 
provide regional quantitative lung function data. In addition to its 
potential use in disease diagnosis, monitoring and assessing 
therapeutic drug efficacy, diffusion imaging can also be used to 
a) b) 
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plan surgery, including tumor resection and lung volume 
reduction surgery for emphysema, as it can aid prediction of 
post-surgery lung function. The predicted post-surgery lung 
function is currently calculated using ventilation or perfusion 
scintigraphy and quantitative CT; however, there is a risk that 
scintigraphy, the most commonly used imaging modality, may 
underestimate post-operative lung function,[97] thereby, 
preventing the patient from undergoing potentially curative 
surgery. 
3.7. Dissolved Phase Imaging 
129Xe (in contrast to 3He) is highly lipophilic and soluble in 
biological tissues and thus is able to provide information on gas 
exchange and pulmonary perfusion particularly interesting in the 
context of functional lung imaging.[98] It is the associated 
persistent exchange of 129Xe between the gas and dissolved 
compartments, each with its own different resonance 
frequencies, that is central to assessing gas exchange using 
129Xe-MRI.[99] Therefore, combined imaging of the gas phase 
129Xe and the dissolved phase 129Xe would permit 
ventilation/perfusion (V/Q) imaging—and consequently a more 
direct mapping of lung function.[87] Hence, although 129Xe-MRI 
initially lagged behind 3He-MRI, developmentally, 129Xe-MRI is 
likely to be the pragmatic HP noble gas MRI modality of choice. 
Figure 4. 129Xe NMR spectra recorded from two healthy volunteers. Two 
dotted lines have been placed to represent the expected dissolved state peaks, 
the left most line representing the expected ~196 ppm lung parenchyma peak, 
and the right most line representing the expected 216 ppm red blood cell peak. 
S. Hardy, B. Haywood, M. Barlow, S. Safavi & I. Hall - University of 
Nottingham (Unpublished work). 
 
Although the majority of the inhaled 129Xe remains in the 
airspaces, where it exhibits its primary gas-phase resonance, a 
portion dissolves in alveolar septa and crosses the alveolar-
capillary barrier to dissolve in the blood. The resulting shift in the 
resonance frequency leads to the appearance of two additional 
distinct resonances: 1- the barrier resonance, and 2- the 
hemoglobin-associated 129Xe resonance, as seen in Figure 4 
(We note the intensity differences between the two spectra are 
due primarily to the variation in the amount and speed at which 
hyperpolarised xenon gas was inhaled by the two volunteers. As 
volunteers became more familiar with the breathing protocol, the 
improvements in both ventilatory image quality and dissolved 
phase signal/noise were noted). This transfer pathway is 
identical to that followed by oxygen; therefore, in addition to 
being a ventilation probe, 129Xe is also a gas diffusion transfer 
probe.[94a] 
The signal intensity of the dissolved phase 129Xe is 
approximately 2% of that remaining in the alveolar spaces, 
which presents a challenge to obtaining good quality images.[94a] 
However, as the alveolar space, alveolar septa, and capillary 
blood are in dynamic exchange, it is possible to use nearly all of 
the inhaled gas to generate 3D images of dissolved 129Xe in a 
single breath-hold, as demonstrated in a number of studies.[94a, 
100] 
Another challenge is to distinguish between xenon dissolved 
in the alveolar septa and that dissolved in the blood. Various 
teams have used the chemical shift and the change in 
resonance frequency to distinguish xenon in these two 
compartments[98a, 101] as the dissolved-phase 129Xe signal splits 
into two distinct peaks in alveolar septa and blood. These 
methods, known as the Xenon Polarization Transfer Contrast 
(XTC)[98a, 101b, c] and the Model of Xenon Exchange (MOXE),[101a, 
d, e] have been assessed in healthy volunteers[102] and patients 
with obstructive lung disease,[102a] with promising results. 
Further testing these methods, Kaushik et al.[94a] 
hypothesized that there will be a reduction in 129Xe signal 
intensity in the hemoglobin: alveolar septum ratio in patients with 
idiopathic pulmonary fibrosis (IPF), due to the thickening of the 
alveolar septa in this condition. MR spectroscopy was used to 
demonstrate the change in signal intensity in patients with IPF 
compared to healthy volunteers. The ratio was significantly lower 
in the IPF group compared to the healthy volunteer group, due 
to a 52% reduction in the hemoglobin signal and a 58% increase 
in the alveolar septa signal. There was a strong correlation 
between the hemoglobin: alveolar septum ratio and TLco. 
Therefore, this technique appears to provide a non-invasive 
measure of diffusion limitation and gas transfer impairment. 
These findings suggest that 129Xe-MRI has the potential to 
detect subtle lung function deterioration before irreversible 
structural changes become apparent, providing clinicians with 
the chance to offer therapy (when available), at an earlier stage 
in order to reverse, halt, or delay disease progression. 
3.8. Neuroimaging 
129Xe-MR brain imaging is emerging as a distinct possibility. Just 
as xenon can be used as a gas exchange probe due to its ability 
to dissolve across the alveolar-capillary barrier, it can also be 
used as a cerebral blood flow (CBF) probe, as it can cross the 
blood-brain barrier and accumulate in the brain.[103] First used in 
its non-polarized form for CBF measurement using CT in 
1982,[104] Swanson et al.[105] were the first group to publish data 
on brain MR imaging using HP 129Xe as an inhaled 
neuroimaging contrast agent, albeit in rats. Animal studies have 
continued over the past two decades, using HP 129Xe as both an 
inhalational[106] and injectable contrast agent.[107] 
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Diseased states have also been imaged in the rat model. 
Xenon signal in the brain is proportional to CBF, hence a 
decrease in the signal is expected to occur in areas of 
decreased CBF, such as those expected in ischemic stroke. 
Working on this principle, Zhou et al.[108] created a rat model of 
cerebral ischemia by using an intraluminal suture to occlude the 
middle cerebral artery, and demonstrated 129Xe-MRI is able to 
detect the hypo-perfused area of focal cerebral ischemia, which 
was also confirmed on biopsy. Mazzanti et al.[109] further 
demonstrated the capacity of 129Xe-MRI for functional 
neuroimaging by inducing pain in the rat’s forepaw, and 
obtaining 129Xe-MR images, which showed 13-28% increase in 
signal compared to the pre-stimulus images; these regions of 
increased signal corresponded to areas previously 
demonstrated by conventional functional MRI (f-MRI) as being 
activated by a forepaw pain stimulus. 
It remains to be seen whether 129Xe-MR neuro-imaging is 
feasible in humans and of value but developmental work is on-
going. 
3.9. Conclusion 
Biomarkers of disease can be classified into diagnostic, 
prognostic, and theranostic. The ideal biomarker encompasses 
all groups, and 129Xe-MRI has the potential to provide diagnostic, 
prognostic and theranostic biomarkers. 
4. Brown-Fat MRI using Dissolved 
Hyperpolarized 129Xe 
For biological MR applications, one of the most interesting 
properties of HP xenon is its high tissue solubility and its 
chemical shift sensitivity to its molecular environment. However, 
MR imaging and spectroscopy applications of dissolved-phase 
HP xenon have been limited to brain and lung tissues (as 
described in the sections above), as the concentration of 
dissolved-phase xenon in other tissues is rarely high enough to 
yield good signal after the typical single breath-hold protocol 
used for human studies. Neglecting nuclear spin relaxation and 
magnetization loss due to NMR pulsing, the time dependence of 
xenon concentration in tissues Ci(t) is well described by the 
Kety-Schmidt equation:[110] 
   𝐶𝑖(𝑡) = 𝜆𝑖𝐶𝑎 (1 − 𝑒
−
𝐹𝑖
𝜆𝑖
𝑡
), 
 
where i, is the xenon partition coefficient between tissue and 
blood, Ca is the arterial concentration of the inert gas, and Fi. is 
the blood flow to the tissue of interest. For most tissues, i, 
which determines both the maximum concentration achievable 
in a given tissue and the time it takes to achieve maximum 
concentration, is close to unity.[111] However, Fi, which also 
determines wash-in rate, varies widely. For example, blood flow 
to the brain is very high (~0.5 L/min/kg) and the maximum xenon 
concentration in this tissue can be reached after a few seconds 
from the beginning of gas inhalation. On the other hand, while 
the solubility of xenon in fatty tissues is almost 20 times higher 
than in blood, because of the low tissue-perfusion (~0.01 
L/min/kg), saturation can only be reached after several minutes. 
For HP 129Xe gas, this is a clear limitation, as gas depolarization 
would limit the amount of detectable signal even under 
continuous HP xenon inhalation. 
It was recently shown that the intensity of the xenon 
dissolved-phase signal could reach much higher levels than in 
the brain in a tissue called Brown Adipose Tissue (BAT).[112] 
Brown adipose tissue is a fatty tissue found in most mammals, 
including humans, and its primary function is to generate heat 
through a process called non-shivering thermogenesis.[113] 
During stimulation of non-shivering thermogenesis in this tissue, 
intracellular triglyceride oxidation is decoupled from ATP 
production so that triglycerides are mainly burned to produce 
heat. To support this metabolic activity, BAT is richly 
vascularized. During non–shivering thermogenesis, tissue 
perfusion increases by several fold as blood flow is needed to 
support the tissue’s oxygen demand and to quickly dissipate the 
heat produced. 
Aside from its thermoregulatory function, BAT has recently 
gained a great deal of interest because of its presumed role in 
the regulation of body weight and blood glucose level. For 
example, a series of studies in rodents have clearly shown that 
BAT function can directly regulate body weight and improve 
insulin sensitivity.[114] However, the detection of this tissue still 
remains a challenge, especially in humans,[115] where it is 
sparsely distributed and not easy to detect by standard MR 
techniques. In the paper by Branca et al.,[23] a strong 
enhancement of the intensity of the xenon-dissolved phase 
signal was reported in mice inhaling HP 129Xe right after 
stimulation of non-shivering thermogenic activity in BAT, an 
effect which was ascribed to the strong enhancement in blood 
flow to BAT.[116] Blood flow to this tissue during stimulation can 
reach values as high as 5 L/min/kg,[116] considerably reducing 
xenon wash-in rate and allowing it to reach an in-tissue 
concentration of 10s of mM. Since the increase in blood flow is 
specific to brown fat cells, background free maps of this tissue 
could be generated. 
More interestingly, it was also shown that xenon chemical 
shift information can provide a measure of the relative tissue 
hydration and tissue temperature. Specifically, two major peaks 
were observed in these studies. One signal, at ~197 ppm, 
corresponding to xenon dissolved in cell cytoplasm/blood, and 
one signal corresponding to xenon dissolved in the lipid droplets 
of the tissue (~190 ppm), and these signals are challenging to 
separate in mice). The lipid-dissolved peak was shown to have a 
temperature-sensitive chemical shift (-0.2 ppm/°C), which 
enabled direct measurement of the increase in tissue 
temperature (Figure 5) during non-shivering thermogenesis.[23] In 
addition, during non-shivering thermogenesis, a relative 
decrease of the lipid-dissolved phase peak was observed with 
respect to the cytoplasm/blood peak, yielding direct evidence of 
this tissue’s oxidative metabolism of internal triglycerides. 
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Figure 5. 129Xe brown adipose tissue (BAT) temperature map overlaid on a 
sagittal 1H image. These temperature maps were obtained by using the lipid-
dissolved xenon signal as a temperature probe. The temperature coefficient of 
the lipid-dissolved xenon chemical shift was measured to be -0.2 ppm/°C. 
 
More recently, the feasibility of BAT detection in humans during 
a single breath hold of HP xenon was demonstrated, with 
validation by FDG-PET.[117] As in mice, a strong increase in the 
lipid dissolved xenon signal was seen in the same glucose-avid 
area of the supraclavicular fat depot. More interestingly, xenon 
spectra showed, in addition to the lipid-dissolved phase peak, a 
nearby peak around 200 ppm that was attributed to xenon 
dissolved in red blood cells (RBCs), a signal that provided direct 
evidence of the strong increase in tissue blood flow as the main 
drive for the increase in xenon tissue uptake. 
By being a highly vascularized fatty tissue, BAT is clearly an 
easy target for the lipophilic xenon. In this case, HP 129Xe gas 
MRI is a “one-stop shop” for human BAT studies as it is capable 
of providing both morphological and functional information. 
5. 129Xe Cages and Hyper-CEST MRI 
5.1. Bound xenon and molecular hosts 
In addition to the NMR study of HP Xe in the gas phase and the 
studies of tissue-dissolved Xe as described above, the affinity of 
xenon to reside in hydrophobic pockets enables additional 
insights, This phenomenon made xenon a tool for exploring 
binding sites on protein surfaces[2c] with some effort being put on 
spin polarization transfer to nuclei in nearby residues that form 
the catalytic site of enzymes. Hence, detection of proton signals 
with and without adding HP nuclei could identify the pocket-
related residues.[111] Xe NMR spectra themselves can also show 
signals indicative of bound atoms. Such a population could 
either cause a shift of the dissolution peak or a distinct signal 
given the exchange rate would fall into the right regime.[112] An 
example are red blood cells[113] where the signal of “bound” Xe is 
ascribed to the interaction with hemoglobin.[118] Several 
experiments first used lyophilized protein powder samples, e.g. 
of lipoxygenases.[119] NMR of dissolved Xe has been applied to 
identify binding pockets of lipid transfer protein,[120] and for 
observation of conformational changes in maltose binding 
protein,[121] and chemotaxis Y protein.[122] Besides specific site 
affinity for native structures, protein engineering also allowed for 
the design of conformation-sensitive binding pockets as 
demonstrated with the ribose binding protein.[123] 
The binding of Xe to synthetic hosts where the cavity has a 
simpler design than in proteins can be even more pronounced. 
-cyclodextrin[124] still comes with fast exchange but  cucurbit[n]-
urils[125] (CBn, n = 5,6) show distinct peaks for bound Xe as well 
as cryptophanes, a family of molecular cages with some 
members that show rather high Xe affinity (K > 103 M-1).[126] It 
has been shown that different members of this group show 
distinct signals of bound xenon (Figure 6a). In particular 
cryptophane-A, CrA, is often used for conferring a distinct 
chemical shift to bound Xe ca. 130 ppm upfield from the signal 
of free Xe in aqueous solution. 
5.2. Xenon biosensor concept 
These molecular cages triggered the field of Xe biosensors 
where CrA is used as the NMR-active reporter being tethered to 
a binding unit to reveal the presence of a certain analyte (Figure 
6b). The first implementation was shown with the biotin-avidin 
system.[127] This original publication also introduced the multi-
plexing option that this concept offers. This feature is inherent to 
the different cage types (like in Figure 6a), but also small 
chemical modifications on the cage, e.g. deuteration,[127b] 
already provide a host-guest system with a different resonance 
frequency. Thus the combination of different hosts with different 
targeting units would allow for detecting multiple analytes 
simultaneously.  
The sensing capability initially relied on a change in chemical 
shift and direct detection of the bound Xe signal–a concept that 
was later partially revised due to anticipated loss of spectral 
resolution in cells and live animals. Optimization for this concept 
included first and foremost increasing the Xe affinity and 
maximizing the detected chemical shifts. It is obvious that the 
cage size impacts the binding constant as illustrated in a 
comparative review,[128] but substitutions on CrA and 
cryptophane-111 can also increase the affinity.[129] 
Understanding the details behind the complexation of Xe 
revealed induced fit properties[130] and displacement of water[131] 
as contributing forces. The linker length between cage and 
targeting unit is a critical parameter for enabling the right 
balance between sufficient mobility required for narrow 
resonances and desired surface contact with the target to shift 
the signal.[132] Another relevant aspect of cryptophane-based 
sensors is the poor water solubility of the host. While many 
cages were first characterized in organic solvents, various 
synthesis studies succeeded to improve solubility.[129c, 131, 133] 
5.3. Hyper-CEST signal amplification 
The focus on the binding properties somewhat shifted with the 
advent of MR imaging protocols for such sensors. The low 
concentration of caged atoms (typically < 10-5 M) requires 
extensive signal averaging for conventional detection. Initial 
imaging applications were slow and limited to selected spatial 
dimensions.[134] To improve this situation, the chemical exchange 
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of Xe became an important parameter. One method for 
enhanced sensitivity in spectroscopy applications uses selective 
read-out of the caged Xe signal while the pool of dissolved Xe 
serves as a polarization reservoir.[135] This principle was also 
used in imaging[136] but has its limitations due to the timing that 
comes with frequency selective excitation pulses with defined 
flip angles. 
However, inverting the roles of the participating pools, i.e. 
manipulating the dilute pool and detecting the abundant solution 
pool, enables significant signal enhancements. The method with 
selectively saturating the magnetization from the dilute pool 
(either through cw irradiation, or by using a train of shaped 
excitation pulses) and observing the signal decrease of the other 
pool (Figure 6c) is called chemical exchange saturation transfer 
(CEST), first introduced by Balaban and co-workers.[137] 
Combining CEST with HP nuclei was first demonstrated by the 
Pines lab for an imaging application and coined Hyper-CEST.[138] 
With Hyper-CEST, host concentrations as low as ~10-8 M 
become accessible—even for imaging.[139] The effect strongly 
depends on the exchange rate and therefore it can also sense 
system parameters like ambient temperature.[140] The spectral 
dimension can be recovered by performing a series of 
experiments in which the saturation pulse is swept over a certain 
frequency range (Figure 6d), thus providing another method to 
sense parameters that influence the chemical shift.[141] It also 
preserves the multiplexing option mentioned early on. 
5.4. Xe Biosensor Applications in Cell Biology 
The improved detection limits for imaging made it possible to 
address problems under more biologically realistic conditions. 
To date, cryptophane-based sensors that use specific binding to 
the target have been implemented for sensing the enzyme 
MMP7,[142] nucleotides,[143] human carbonic anhydrase,[144] MHC 
class II,[145] zinc ions,[146] the glycoprotein CD14[147] and the 
receptors for integrin,[148] transferrin,[149] EGF,[150] and folate.[151] 
An indirect binding approach was pursued through in situ click 
chemistry with metabolically labeled cell surface glycans.[152] 
Conformational changes of the sensor induced by changes in 
pH represent an approach for stimulus-induced binding.[153] 
As part of these studies, cell uptake and toxicity evaluations 
set the bar for target concentrations of functionalized hosts.[148, 
154] Xe itself passes the cell membrane[149] and does not require 
further attention to reach intracellular targets. Cell-penetrating 
peptides proved to be a valuable measure for achieving 
micromolar intracellular concentrations. However, they are not 
an absolute requirement since the hydrophobic character of CrA 
can mediate membrane-association and therefore enables 
certain types of cellular labeling.[155] Sensors with highly specific 
binding motifs (e.g., antibodies[147, 150] or bioorthogonal reaction 
partners[152]) only require sample-averaged concentrations of 10-
8 M for MRI. 
Critically, the membrane affinity of CrA can be clearly 
identified by a ca. 10 ppm downfield shift for Xe in membrane-
associated CrA.[156] This property proved primarily useful to 
identify cell-associated cages in the first live-cell experiments.[149, 
155a] A closer look in combination with FRET data revealed 
partitioning coefficients on the order 102-103 for different 
membrane compositions.[157] This work also initiated a new class 
of Hyper-CEST experiments for investigating membrane fluidity 
and integrity: Due to the accelerated exchange, Xe signals from 
membrane-embedded cages do only differ marginally in 
chemical shift. However, build-up of the CEST effect can be very 
different depending on membrane fluidity. Comparative studies 
are possible when irradiating a pool of caged Xe at fixed 
saturation power and frequency but increasing saturation time. 
Evaluating the (multi-)exponential depolarization with an inverse 
Laplace transformation yields characteristic time constants for 
different environments.[158] The method called DeLTA 
(depolarization Laplace transform analysis) can also be used to 
discriminate cholesterol content and the onset of lipid domain 
fluctuations.[159] 
5.5. Host Optimization 
In order to explore a large chemical shift range of different 
sensors, the impact of metal ion chelation in close proximity to 
the cage provides a means to diversify signals.[160] Along this line, 
attached Gd-chelates can serve as relaxation switches for 129Xe 
which are detachable through chemical reactions.[161] Regarding 
Hyper-CEST detection, improved efficiency depends on the 
exchange properties, which are sub-optimal for CrA. Faster 
exchanging hosts such as CB6[162] and CB7[163] are currently 
under investigation. Their binding properties for competitive 
guests must be taken into account but this versatile binding 
phenomenon on the other hand enables the option to implement 
detection of other guests via displacements approaches. An 
example is the mapping of lysine decarboxylase LDC activity 
where the enzymatic product cadaverine quenches the Hyper-
CEST effect.[163] Related to this is an implementation of a sensor 
relay in which the cavity becomes accessible for Xe as soon as 
another host recruits the original guest from the CB6 cavity.[164] 
The macrocyclic host also allows construction of rotaxanes that 
keep the cavity blocked. Cleaving one of the rotaxane stoppers 
releases the thread and makes CB6 available for Hyper-CEST 
detection.[165] This recent design could serve as a development 
platform for various sensors based on cleavage reactions. 
Many dilute targets will only be accessible with an increased 
number of CEST sites per targeting unit. For this purpose, 
multivalent carriers with 102 – 103 Xe hosts will be the right tool. 
They have been implemented with scaffolds such as bacterial 
phages,[150, 166] viral capsids,[167] and liposomes.[168] Alternatively, 
nano-compartments absorbing small amounts of Xe gas can be 
used, one example being PFOB nanodroplets.[169] The first 
imaging experiments with the latter substance also included the 
first multi-channel read-out of different host classes.[155b] Similar 
host compartments such as gas vesicles[170] and bacterial 
spores[171] will be discussed separately in the following section. 
5.6. Hyper CEST analysis and data encoding 
Stable and reproducible HP Xe delivery with shot-to-shot noise < 
1% achieved through temperature stabilization of the pumping 
cell[172] allows one to further investigate the predicted line-shape 
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for Hyper-CEST spectra, i.e. an exponential Lorentzian.[173] 
Linked to this theoretical description is an approximation for the 
Bloch-McConnell equations that allows prediction of the build-up 
of the Hyper-CEST effect and quantification of the exchange 
parameters.[174] Comparison of hosts can then be done by using 
the gas turnover rate.[162b] The exchange dynamics also set the 
boundary conditions for maximum signal contrast and an 
orientation for optimum saturation parameters.[175] It is important 
to achieve the saturation transfer before the intrinsic T1 
relaxation dominates with its signal loss. 
 
Figure 6. Caged Xe biosensor concept, and Hyper-CEST detection. a) 
Different Xe hosts confer different chemical shifts to the bound atoms that 
enable readout at distinct resonance frequencies. b) Xe inside a molecular 
host changes its resonance frequency upon binding to a target structure. c) 
Selective Hyper-CEST saturation at one of these frequencies causes a cloud 
of depolarized Xe around the respective host. The reduced signal from free Xe 
represents an amplified information from the small amount of cages. d) 
Sweeping the saturation pulse over a certain frequency range and subsequent 
observation of the magnetization from free Xe yields a Hyper-CEST spectrum 
for comparing the performance of different hosts. 
For imaging, the CEST information needs to be encoded as fast 
as possible. Fast imaging sequences can replace the original 
point-wise encoding[138] given sufficient magnetization. Echo 
planar imaging (EPI) allows sub-second imaging,[139] with 
particular application to hyperpolarized imaging using variable 
flip-angle excitation in an approach called smashCEST. These 
rapid imaging approaches enable time-resolved studies, 
including the monitoring of diffusion.[139] Image quality can be 
improved by exploiting redundancies in the spectral domain[176] 
during encoding and post-processing. Spin-echo encoding is an 
alternative for cases where T2* relaxation makes EPI encoding 
impractical.[155a] 
Interest in Hyper-CEST agents has led to the development of 
fast strategies for gradient-encoded CEST spectra at up to 40-
fold reduced scan times.[177] 
6. Genetically Encodable Hyperpolarized 129Xe 
MRI Contrast Agents 
Genetically encoded MRI reporters are contrast agents that can 
be produced by genetically transfected cells to enable the 
tracking of cells, imaging of gene expression, or sensing of 
specific aspects of cellular function. Among the advantages of 
these reporters over synthetic agents are that they can be 
introduced into cells using established gene-delivery techniques, 
avoid dilution with cell division, and that a large genetic 
engineering toolbox can be used to modify and optimize protein-
based reporter performance. Furthermore, these agents 
leverage the recent boom in molecular biology methods to 
manipulate and deliver genetic materials to animals, such as 
transgenic mouse lines, viral therapy, RNA interference, and 
genome editing. 
Most existing genetic reporters have been designed for 1H 
MRI. Examples include enzymes or transporters that can act on 
synthetic contrast agents,[178] proteins that naturally contain 
paramagnetic metals, including ferritin,[179] MagA,[180] MntR,[181] 
tyrosinase,[182] and cytochrome P450,[183] and diamagnetic CEST 
agents such as lysine rich-protein,[184] human protamine 
sulfate[185] and proteins that alter water diffusivity in tissue.[186] 
Comparatively fewer contrast agents have been designed for 
heteronuclear MRI, all of them based on enzymatic or 
transporter interactions with 19F compounds,[187] HP 13C 
compounds,[187c, 188] or 31P substrates.[189] A major challenge of 
all of these agents is their relatively low molecular sensitivity, 
typically of the micromolar or higher order, which limits their 
range of in vivo applications. Several excellent reviews have 
been written on these classes of MRI reporters.[190]  
Given the sensitivity gains of HP 129Xe MRI and in particular 
HyperCEST, there is a strong incentive to develop genetically 
encoded MRI reporters acting on xenon. However, this prospect 
is challenging due to the weak interaction of xenon with most 
proteins. Xenon-binding proteins have been identified through X-
ray crystallography, wherein xenon is used as a heavy atom 
marker to aide in structure elucidation,[191] and NMR, wherein the 
129Xe chemical shift can probe proteins’ confirmation and ligand 
binding.[192] Examples of proteins shown to interact with xenon 
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include myoglobin[193] and hemoglobin, maltose binding 
protein[112] and lysozyme[119]. These interactions are attributed 
primarily to enthalpic Debye and London interactions, with a 
smaller entropic contribution from xenon dehydration as it enters 
a hydrophobic cavity.[192b] Unfortunately, although protein binding 
was shown to shift the resonance frequency of xenon by several 
ppm/mM, these proteins are not suitable as 129Xe-MRI contrast 
agents because their xenon affinities (~10 mM) would require 
unrealistic quantities of protein to be present to achieve 
significant direct contrast, while their xenon exchange rates 
(dissociation constant ~ 105 s-1)[193] are too fast compared to the 
induced xenon chemical shift (Δω ~ 103 - 104 s-1) to enable 
efficient HyperCEST contrast. 
A major advance in the development of genetically encoded 
reporters for Xe-MRI was made in 2014, when Shapiro et al. 
reported that an unusual class of gas-filled protein 
nanostructures called gas vesicles (GVs) could produce efficient 
HyperCEST contrast at picomolar concentrations.[25] GVs, which 
evolved in photosynthetic microbes as a means to regulate 
buoyancy, comprise hollow gas compartments at hundreds of 
nm in size and possess a 2 nm protein shell that is permeable to 
gas but excludes liquid water[194] (Figure 7a,b). Shapiro et al. 
showed that GVs can interact with xenon to produce 
HyperCEST contrast with peak saturation approximately 175 
ppm upfield from dissolved 129Xe (Figure 7c,d). The large 
chemical shift separation enables the contrast to be extremely 
efficient, with a GV detection limit in the picomolar range (Figure 
7e), orders of magnitude lower than comparable proton contrast 
agents.  Furthermore, GVs formed by different species of 
bacteria and archaea, in which these nanostructrues differ in 
size and shape, produce HyeprCEST saturation at different 
chemical shifts, thereby enabling multiplexed imaging. In their 
initial study, Shapiro et al. provided proofs of concept for GVs as 
antibody-functionalized markers of cancer cells and as reporters 
of gene expression in E. coli. In addition to GVs, other biological 
structures may be able to serve as HyperCEST agents. For 
example, bacterial spores, a dormant cellular state comprising a 
multi-layered structure of ~ 1.5 µm size, were recently 
demonstrated for HyperCEST at a chemical shift 4.5 ppm 
downfield from aqueous xenon.[171] 
The discovery of GVs as highly efficient biomolecular 
reporters for HyperCEST leads to several interesting questions 
and possibilities that merit further investigation. If we assume 
that an optimal CEST saturation can always be achieved with 
sufficient RF power and that the relaxation of 129Xe is minimal 
during CEST experiment, then HyperCEST sensitivity is 
determined by (a) the chemical shift difference and (b) the 
exchange rate between the contrast-agent-bound and the 
dissolved 129Xe spins.[195] Regarding the chemical shift, each GV 
has a several-attoliter gas chamber containing thousands of gas 
atoms or molecules, where 129Xe atoms presumably experience 
an environment similar to gas phase, and consequently 
compared to the synthetic contrast agents, GV-associated 129Xe 
chemical shift is usually closer to that of the gas phase. 
Intriguingly, the specific value of chemical shift appears to be 
genetically determined.[25] It will be interesting to study how this 
chemical shift relates to other genetically encoded GV properties, 
including their size, shape and aggregation state, and the extent 
to which these properties can be tuned at the genetic level. In 
terms of the exchange rate, when the Z spectra (i.e. the 
frequency-dependent saturation effects are visualized similar to 
conventional magnetization transfer spectra by plotting the water 
saturation (Ssat) normalized by the signal without saturation (S0) 
as a function of saturation frequency) acquired with intact and 
collapsed GV are compared with those acquired with synthetic 
agents, both the GV-bound and the dissolved 129Xe peaks 
appear to be broader, suggesting the exchange rate is in the 
intermediate regime. It will be interesting to define quantitatively 
the optimal RF saturation parameters for the specific exchange 
rate of GVs. On the molecular level, though the atomic-level 
structure of the GV wall has not been solved, some hypotheses 
have been proposed regarding the channels on the protein shell 
that allow gas exchange in and out of the nanostructure[194b]; it is 
possible that variation (natural or engineered) in the amino acid 
sequence of GV proteins could alter the permeability of these 
putative pores. Taken together, GVs present a wide dynamic 
range for 129Xe chemical shifts and exchange rates, and these 
two properties are likely amenable to protein engineering for 
new and optimized forms of 129Xe HyperCEST. 
 
Figure 7. Gas vesicles as genetically encodable HyperCEST reporters 
detectable at pM concentrations. (a) Diagram of a gas vesicle: a hollow gas 
nano-compartment (solid shading) surrounded by a gas-permeable protein 
shell (ribbed shading). (b) Transmission electron micrographs of individual 
GVs purified from Halobacterium NRC-1 in their intact (left) and collapsed 
(right) state. (c) Diagram of 129Xe CEST between bulk aqueous solvent (left) 
and GVs (hexagons) either in isolation or inside a cell (gray). (d) Frequency-
dependent saturation spectra for intact (red) and collapsed (black) GVs. (e) 
Saturation contrast image of a three-compartment phantom containing 400 pM 
GVs, 100 pM GVs and buffer. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Chemistry,[170] copyright 2014. 
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It is also worth noting that in addition to serving as 
HyperCEST reporters, GVs produce contrast in at least two 
complementary imaging modalities. First, they are the first 
genetically encodable imaging agents for ultrasound,[196] where 
their low density and high elasticity relative to surrounding media 
allows them to scatter sound waves. Secondly, their gas-filled 
interior, which has a different magnetic susceptibility from 
surrounding solution, allows GVs to produce 1H MRI contrast in 
susceptibility-weighted imaging.[197] 
The list of genetically encoded 129Xe-based HyperCEST 
reporters has been recently expanded to include β-Lactamase 
by Dmochowski and co-workers.[198] As a small protein encoded 
by a single gene, this reporter may be easier to use in some 
settings than GVs, albeit with somewhat lower molecular 
sensitivity. 
7. Parahydrogen 
Hydrogen exists in two nuclear spin isomers denoted as ortho- 
and para- corresponding to the nuclear triplet and singlet states, 
respectively, where parahydrogen corresponds to the states with 
an even rotational quantum number J whereas orthohydrogen 
corresponds to odd values of J. The ratio of the two isomers is 
determined by the Boltzmann thermal equilibrium for the given 
rotational state J, Figure 8.[199] For a more detailed discussion of 
the physics and applications of parahydrogen beyond the scope 
of this mini-review, we refer the interested reader to the 1935 
book by Farkas on hydrogen[199] or various excellent 
discussions.[200] 
 
Figure 8. Parahydrogen conversion. Passage of H2 gas over a paramagnetic 
catalyst, given sufficient contact time, converts the ortho-H2 fraction to para-H2 
fraction as a function of temperature. 
Importantly, conversion between the two states occurs 
extremely slowly due to the transition being forbidden by the 
selection rules of quantum mechanics, leaving only statistically 
unlikely naturally occurring processes of sufficient energy 
(radiation, molecular collisions, etc.) to foment interconversion. 
Therefore, after its production (and provided lack of exposure to 
sources of paramagnetic impurities in the storage vessel), 
parahydrogen may be stored for long periods before use, as the 
relaxation rate of the parahydrogen back to room-temperature 
equilibrium can be on the order of months.[201] Production rates 
are significantly faster, however, since as discovered in 1929 by 
Bonhoeffer and Harteck, the use of paramagnetic catalysts (i.e. 
activated charcoal, nickel, hydrated iron (III) oxide) promotes 
establishment of Boltzmann thermodynamic equilibrium between 
ortho-H2/para-H2 states for a given temperature at greatly 
accelerated rates. In practice, normal hydrogen gas (i.e. 
equilibrium ratio at room temperature) consisting of 75% ortho- 
and 25% para- isomers is passed through a paramagnetic 
catalyst filled chamber at cryogenic temperatures, where the 
equilibration to the isomer ratio governed by the Boltzmann 
distribution occurs. For example, a parahydrogen generator 
based on 77 K (obtained conveniently by a liquid-N2 bath) yields 
~50% parahydrogen mixture, whereas the designs based on 
cryo-chillers (e.g. T20 K) yield 99% parahydrogen (Figure 8). 
8. Fundamentals of Parahydrogen-Induced 
Polarization (PHIP) 
In 1986 Russ Bowers and Daniel Weitekamp proposed a 
method for achieving very high nuclear polarizations using 
parahydrogen.[7a] Dubbed PASADENA (Parahydrogen And 
Synthesis Allow Dramatically Enhanced Nuclear Alignment), the 
effect predicted strongly enhanced 1H NMR signals for 
hydrogenation reaction products when unsaturated molecular 
precursors are hydrogenated with parahydrogen. Later they 
demonstrated the effect experimentally by hydrogenating 
acrylonitrile with parahydrogen using Wilkinson’s catalyst.[7b] 
Anti-phase 1H NMR multiplets were demonstrated for the 
reaction product, propionitrile, and for dihydride rhodium 
complex – the reaction intermediate. It was later realized that 
experimental demonstrations of the PASADENA effect had 
already been published,[202] but had been misinterpreted as 
chemically-induced dynamic nuclear polarization.[7c] PASADENA 
and (the later discovered) ALTADENA[203] are collectively 
dubbed as the process denoted as parahydrogen-induced 
polarization (PHIP).[11c] This seminal discovery of Bowers and 
Weitekamp opened up a new strategy for hyperpolarization of 
various compounds, and currently PHIP and its recent 
modification, SABRE (Signal Amplification By Reversible 
Exchange),[8] are used to obtain HP molecules with 1H,[11c, 200b] 
13C,[12] 15N,[13d] 19F,[14] and 31P[15] nuclei in a hyperpolarized state. 
Detailed explanation of the spin dynamics and chemical kinetics 
behind PHIP can be found in several comprehensive reviews.[11c, 
200, 204] Here we briefly discuss the main principles of PHIP to 
qualitatively describe the phenomena discussed below. As an 
example, we take the simplest two-spin system. The two-spin 
system of the hydrogen molecule gives rise to four nuclear spin 
energy levels. As described above, three of these energy levels 
correspond to orthohydrogen, the state with total nuclear spin 1 
(triplet state), whereas the remaining fourth energy level 
corresponds to parahydrogen (singlet state), the state with zero 
total nuclear spin. Transitions between singlet and triplet spin 
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states are forbidden by symmetry;[7a] and the spin 0 
parahydrogen is NMR-silent. 
Bowers and Weitekamp’s idea was to break the magnetic 
equivalence of two hydrogen nuclei by using parahydrogen in a 
hydrogenation reaction (Figure 9a), thus, making prohibited 
transitions allowed. Indeed, upon incorporation of a 
parahydrogen molecule into an asymmetric molecular precursor, 
the symmetry of the para-H2 molecule becomes broken. This 
situation strongly depends on the magnetic field at which the 
hydrogenation reaction takes place. If hydrogenation is 
performed at high magnetic field B0 (i.e., wherein the chemical 
shift difference between the two para-H2-nascent protons, Δ𝛿, is 
much greater than the spin-spin coupling J between them 
(𝛾Δ𝛿𝐵0 > 2𝜋𝐽 )), then the population of the singlet spin state 
(𝛼𝛽 − 𝛽𝛼 ) of para-H2 is transferred to the population of spin 
states 𝛼𝛽 and 𝛽𝛼 of the formed weakly coupled AX spin system 
(PASADENA effect, Figure 9b).[7b] The NMR spectrum of the AX 
system populated in this way will contain four peaks grouped in 
two antiphase multiplets (Figure 9b). Two lines (positive-
negative or negative-positive, depending on the sign of spin-spin 
coupling constant J) in each multiplet are separated by J Hz in 
the case of isotropic liquids and/or gases.[205] PASADENA-
hyperpolarized organic molecules are typically manifested in 1H 
NMR spectra as positive-negative multiplets, whereas multiplets 
for hydride intermediates are negative-positive, since through-
electron mediated J couplings are negative for metal 
hydrides.[206] Interestingly, signal intensity of PASADENA 
spectrum is maximized when 45o (instead of 90o) pulse is 
applied for signal acquisition, which may be shown using density 
operator description of the PHIP process.[204] 
 
Figure 9. a) Molecular diagram of parahydrogen (para-H2) addition to the 
substrate performed with a homogeneous or heterogeneous catalyst. b) 
PASADENA effect: nuclear spin energy level diagram of para-H2 at high 
magnetic field (left), An AX spin system is formed upon pairwise addition of 
para-H2 to the unsaturated substrate at high magnetic field and corresponding 
1H NMR spectrum (right). c) ALTADENA effect: nuclear spin energy level 
diagram of para-H2 at low magnetic field (left), An AB spin system is formed 
upon pairwise addition of para-H2 to the unsaturated substrate at low magnetic 
field, An AX spin system is obtained after adiabatic transfer of the reaction 
product from low to high magnetic field. The corresponding 1H NMR spectrum 
is shown at right. 
On the other hand, if the hydrogenation reaction takes place 
at low magnetic field (such that 𝛾Δ𝛿𝐵0 ≤ 2𝜋𝐽; e.g., at the Earth’s 
magnetic field), and afterwards the hydrogenation product is 
adiabatically transferred to a high magnetic field, then there is a 
single state that is overpopulated, i.e. 𝛼𝛽 or 𝛽𝛼—depending on 
the sign of the J-coupling constant between the nuclei 
(ALTADENA effect, Figure 9c).[203] In this case spectral pattern 
will consist of four lines grouped in two “integral multiplets” 
simply corresponding to one spin “up” and second spin “down” 
state (Figure 9c). 
In order to be able to observe PHIP for the molecule of 
interest several key conditions must be fulfilled:[11c] 
1. The addition of parahydrogen to the unsaturated precursor 
should occur in a pairwise manner. Pairwise addition implies 
that two hydrogen atoms from the same H2 molecule are 
included in the product molecule together as a pair, thus 
preserving spin correlation between the two proton spins. 
2. The characteristic nuclear spin relaxation time for para-H2-
nascent protons should be longer than the time needed to 
complete the pairwise hydrogenation process. 
3. The magnetic equivalence of the two correlated nuclear 
spins should be broken during the hydrogenation[207] or in the 
product of the hydrogenation reaction.[7b] 
If all of the above-mentioned conditions are fulfilled, the product 
of the hydrogenation reaction will possess a non-equilibrium 
population distribution of its nuclear spin energy levels owing to 
either the PASADENA or ALTADENA process. 
One should note that the final polarization of the 
hydrogenation reaction product does not depend on the 
magnetic field strength, and the polarization obtained by PHIP in 
principle can reach 100% (neglecting spin relaxation and/or 
decoherence).[7a, 204] In principle, enhancement of the NMR 
signal can be as high as several thousand-fold above ordinary 
thermal signals from high-field NMR spectrometers and even a 
million-fold at low magnetic fields. 
Since the hydrogenation reaction does not proceed 
spontaneously, the key component of the system is a catalyst 
(Figure 9a), which (i) enables hydrogenation reaction, and (ii) 
provides efficient pairwise addition of molecular hydrogen to the 
substrate. All hydrogenation catalysts can be classified as 
homogeneous or heterogeneous depending on their phase 
relative to the substrate. Homogeneous catalysts are present in 
the same phase as the to-be-hydrogenated substrate (typically, 
liquid phase), whereas heterogeneous catalysts are present in a 
phase different from the phase of the substrate (usually, a solid 
catalyst and a gaseous or liquid substrate). Since the first 
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demonstration by Bowers and Weitekamp,[7b] homogeneous 
catalysts have become widely used to produce PHIP, which is 
reasonable: it is known that hydrogenation mechanisms using 
metal complexes can usually provide an efficient route for 
pairwise hydrogen addition. For a long time, the feasibility of 
using heterogeneous catalysts for production of PHIP was 
rejected based on the known mechanism of heterogeneous 
hydrogenation, i.e. the Horiuti-Polanyi mechanism. According to 
Horiuti and Polanyi,[208] hydrogen molecules dissociate on metals 
(typically used as heterogeneous hydrogenation catalysts) and 
form a pool of randomly moving free hydrogen atoms, thus not 
fulfilling condition 1 (pairwise addition) above.[209] Nevertheless, 
it was shown that various classes of heterogeneous catalysts, i.e. 
immobilized metal complexes,[9a] supported metal 
nanoparticles,[28b] etc., can enable the PHIP effect. In the current 
mini-review both classes of catalysts are considered. 
9. Gases hyperpolarized via PHIP 
As mentioned in the introduction, MRI of gases suffers from poor 
sensitivity due to their low molecular density compounded with 
the low thermal polarization of their nuclear spins. These 
problems can make it challenging to image gas-filled void 
spaces due to the very low signal-to-noise ratio (SNR) and the 
usually long signal-averaging times, which can be prohibitive for 
many clinical applications. HP noble gases[210] can be used to 
address these issues. However, the production of HP noble 
gases is relatively expensive, necessitating costly hyperpolarizer 
equipment. Moreover, imaging of HP noble gases requires a 
dedicated X-band channel (for the heteronucleus of interest) and 
radio-frequency probe, which are not standard features of 
clinical MRI scanners (although they are becoming increasingly 
prevalent). Therefore, production of non-toxic HP proton-
containing gases via PHIP could be a promising alternative that 
avoids the above technical requirements of HP noble gases. 
9.1. Production of hyperpolarized gases using PHIP 
Historically, experiments with parahydrogen were predominantly 
conducted in the liquid phase, wherein fluids hyperpolarized by 
PHIP reside in a solution along with a homogeneous 
hydrogenation catalyst.[200b] Heterogeneous catalysts can be 
used to separate the HP product from the catalyst.[29, 211] At the 
same time, it is also possible to produce catalyst-free HP gases 
by combining the main advantage of homogeneous (high 
selectivity) and heterogeneous catalysis (easiest catalyst 
separation) by using gas-liquid biphasic hydrogenation. 
Utilization of a homogeneous catalyst dissolved in the liquid 
phase for biphasic hydrogenation of unsaturated gases with 
para-H2 allows one to produce HP gas that is free from 
contamination by the catalyst. In the demonstration of this 
approach it was shown that the reaction product can return to 
the gas phase while retaining a significant degree of 
hyperpolarization.[212] This feature significantly extends the range 
of gases that can be hyperpolarized. It was shown that utilization 
of a simple experimental procedure allows one to achieve signal 
enhancements of 300 for propyne hydrogenation to propylene 
using the bidentate cationic complex [Rh(PPh2-(CH2)4-
PPh2)(COD)]BF4.[212] Another approach for HP gas production is 
the use of homogeneous catalysts based on a judicious choice 
of the metal complex (homogeneous hydrogenation catalyst) in 
which the desired unsaturated substrate is coordinated to the 
metal center.[213] In that case hydrogenation with parahydrogen 
allows the substrate to leave the metal center and to migrate to 
a different phase with preservation of the spin order of the two 
nascent protons derived from the para-H2 molecule. Indeed, it 
was shown that PHIP-hyperpolarized gas can be obtained in a 
catalysis-free regime using a chemical reaction with molecular 
addition of parahydrogen to a water-soluble Rh(I) complex 
carrying a payload of a compound with double (C=C) bonds.[213] 
Hydrogenation of the norbornadiene ligand leads to the 
formation of norbornene, which is expelled from the Rh(I) 
complex to the aqueous phase, but due to its insolubility in water 
HP norbornene quantitatively leaves the solution to the gas 
phase (Figure 10).[213] 
 
Figure 10. ALTADENA 1H NMR spectra of a gaseous stream during bubbling 
of parahydrogen (a) and normal H2 (b) through the solution of 
[Rh(I)(NBD)L]+BF4- in D2O at 70-80 °C. The broad signal labeled “H2” belongs 
to ortho-H2 gas: the resonances labeled with open circles correspond to 
norbornane. c) Diagram of the experimental setup with the NMR detection 
performed in the high field. Reprinted with permission from Kovtunov, K. V.; et 
al. Anal. Chem. 2014, 86, 6192.[213] 
As soon as PHIP was successfully demonstrated in 
heterogeneous hydrogenations over immobilized[9a] and 
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supported metal catalysts,[28b] the production of HP gases over 
these catalysts became an important area of PHIP-related 
investigations. Many different heterogeneous catalysts were 
used for the production of HP gases in the past eight years, with 
the aim to find the catalyst with the highest level of pairwise 
hydrogen addition for a given substrate.[29, 214] Without doubt the 
utilization of a solid catalyst allows one to produce HP gases in 
the continuous-flow regime by passing a mixture of an 
unsaturated substrate with para-H2 through the catalyst layer. In 
this approach, hydrogenation occurs at the Earth’s magnetic 
field and corresponds to the ALTADENA[203] type of PHIP 
experiment. Note that the nature of the heterogeneous solid 
catalyst can have a significant impact on the polarization level, 
and titania-supported metal catalysts were shown to exhibit 
larger PHIP effects compared to metals on other supports.[215] 
The polarization level for HP gases produced over supported 
metal catalysts can be several percent,[28b, 216] and it increases 
with the decrease in the size of the supported metal 
nanoparticles.[217]  
9.2. MRI of hyperpolarized hydrocarbon gases 
Continuous production of HP gases via heterogeneous 
hydrogenation paves the way to the potential practical 
applications for imaging of void spaces by MRI. The first 
experiments were related to MRI visualization of HP propane in 
a NMR tube with a cross-shaped partition or with a series of 
capillaries.[9b] For that work, a mixture of para-H2 and propene 
gas was flowed through a reactor cell with the heterogeneous 
catalyst (e.g. Rh immobilized on titania). After that the product 
(HP propane gas, Figure 11) was transferred to the NMR 
magnet and the ALTADENA enhancement was evident in the 
MR images, Figure 12a. 
For both model samples, detection of the NMR signal of a 
thermally polarized gas did not produced observable images, 
whereas the use of PHIP-polarized propane gas allowed one to 
visualize the corresponding structures of the objects used in the 
experiments.[9b] Importantly, the demonstrated 300-fold signal 
enhancement in the gas-phase MRI is sufficient to image gases 
with a similar spatial resolution as that in corresponding liquid-
phase MRI experiments. The subsequent development of the 
strategies for 1H MRI visualization of both hyperpolarized and 
thermally polarized propane gas for high-resolution MRI 
applications allowed one to significantly decrease the imaging 
time. Compared to FLASH MRI[218] (Figure 12), the use of UTE 
MRI[219] decreases the total imaging time significantly, down to 
the regime sufficient for MRI of a patient within a single breath-
hold in a future clinical translation. It was shown that utilization of 
UTE MRI makes it possible to obtain 2D images of thermally 
polarized with ca. 0.9  0.9 mm2 spatial resolution in ca. 2 s (and 
potentially with better resolution for HP gases).[220] 
Recently, HP propane gas produced by heterogeneous 
hydrogenation of propene over supported metal catalysts was 
utilized for 3D 1H MRI with micro-scale spatial resolution 
(625625625 m3), large imaging matrix size (128x128x32) 
and short (17.4 s) image acquisition time.[215a]  
 
Figure 11. Heterogeneous pairwise hydrogenation of propene to propane with 
para-H2 over Rh/TiO2 catalyst with preservation of spin order of parahydrogen 
in the final HP product. 
 
Figure 12. (a) Schematic representation of the experimental setup for using 
PHIP to produce HP propane via heterogeneous hydrogenation of propene 
with parahydrogen. (b) 1H MRI FLASH image of HP propane flowing into a 10 
mm NMR tube via 1/16 in. OD Teflon capillary. Note that the NMR tube is 
shown schematically and its length does not match the actual scale of the 2D 
MR image. Reprinted with permission from Kovtunov, K. V.; et al. Tomography 
2016, 2, 49.[220] 
 
Figure 13. High-resolution 3D gradient echo (GRE) MRI at 4.7 T. a) 3D MRI of 
flowing HP propane gas (~20 mM concentration) with 0.50.50.5 mm3 spatial 
and 17.7 s temporal resolution and 323232 mm3 field of view. b) The 
corresponding image of (stationary) thermally polarized tap water (55 M). 
Reprinted with permission from Kovtunov, K. V.; et al. J. Phys. Chem. C 2014, 
118, 28234.[221] 
Utilization of a fully deuterated substrate (propene-d6) in the 
heterogeneous hydrogenation with para-H2 permitted acquisition 
of a high-resolution 3D MRI image of flowing HP propane-d6 gas 
with 0.5  0.5  0.5 mm3 spatial and ~18 s temporal resolution 
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(Figure 13a).[221] It was shown that the signal-to-noise ratio in the 
3D images of HP propane-d6 gas (Figure 13a) and water (Figure 
13b) are similar. This observation confirms that the utilization of 
a gas hyperpolarized by PHIP allows one to obtain MR images 
with quality similar to that obtained with water as the signal 
source. 
Utilization of HP gases produced by PHIP is not limited only 
to void space imaging. Indeed, it was shown that a catalytic 
reactor positioned inside an NMR magnet can be imaged in situ 
during heterogeneous hydrogenation of propene to propane with 
parahydrogen.[28a] In situ MRI of a catalytic reaction allows one 
to visualize the regions in the catalyst layer where the 
hydrogenation reaction occurs. Importantly, based on the 
significant signal enhancement the velocity map for HP gas 
forming in and flowing through the catalyst bed was obtained.[28a] 
Given the above results, PHIP is clearly becoming an 
important technique for signal enhancement in both fundamental, 
basic science and biomedical MRI investigations. Moreover, the 
use of PHIP to produce HP gases can be useful for their 
potential utilization in medical MRI applications. 
10. Remote-detection MRI of Hyperpolarized 
Gases 
MRI of gases in small voids, such as in porous media, 
microreactors, and microfluidic devices, suffers from particularly 
low sensitivity due to an additional exacerbating factor: low filling 
factor in the NMR coil, which may be less than 10-5 in some 
cases. While HP methods partially compensate for the low 
sensitivity, an additional sensitivity boost provided by alternative 
detection methods may be required. These methods include, for 
example, surface RF microcoils, RF microslots, and remote 
detection (RD), to name a few.[222] 
In RD MRI,[223] encoding of spatial information and signal 
detection are performed with different coils (see Figure 14a). 
The encoding RF coil is a large coil around the whole sample, so 
that all spins can be excited. Signal detection is performed 
outside the sample with a much smaller and more sensitive RF 
coil, with an optimized filling factor.[224] The technique requires 
that the encoded spins are transported to the detector before the 
magnetization is fully relaxed, and it inflicts one additional 
dimension as compared to conventional MRI, because it is 
based on phase encoding only. Nevertheless, it provides a 
substantial sensitivity boost as an ultrasensitive detection 
solenoid may be hundreds of times more sensitive than the 
encoding coil.[225] Furthermore, the flow delivers spins from the 
different parts of the sample to the detector at different times, 
and this inherent time dimension can be utilized to produce time-
of-flight (TOF) flow images.[226] 
10.1. Time-of-flight flow imaging with HP gases 
HP Xe is an ideal probe fluid in RD MRI experiments, because 
the T1 relaxation time of 129Xe can be extremely long, allowing 
correspondingly long transport times from the sample to the 
detector. HP Xe RD MRI has been used for imaging flow 
through porous materials,[223, 227] rocks,[226] microfluidic 
devices,[225] and wood,[228] as well as for quantifying diffusion 
through membranes.[229] Figure 14b shows a remarkable 
example of 3D TOF images of HP Xe flowing through a rock 
sample. The shortest TOF image (TOF = 0.27 s) shows spins 
that were at the top of the encoding region, because they arrived 
first to the detector, and the longest TOF image (TOF = 0.98 s) 
shows the spins at the sample bottom. 
Gaseous HP hydrocarbons produced by PHIP have been 
used in RD MRI experiments as well.[230] T1 values for spins of 
hydrocarbons are typically much shorter (~ 1 s) than that of 
129Xe, limiting the transport time of fluid from the sample to the 
detector; however, if the sample coil and the detection coil are 
close enough and the flow rate is sufficiently high, the 
experiments are feasible. Because the gyromagnetic ratio and 
the natural abundance of 1H is much higher than for 129Xe, the 
sensitivity in PHIP experiments may be significantly higher.
 
Figure 14. RD MRI of flow of HP 129Xe through a rock sample. (a) The rock sample is inside a large RF coil used to encode spatial information into spin 
coherences, and the signal is read out by a smaller and more sensitive coil around the outlet tubing, with optimized filling factor. (b) 3D TOF images. The 
silhouettes represent the rock sample. TOF, i.e., the time instant the signal is detected after the encoding, is shown above the images. Reprinted with permission 
from Granwehr, J.; Harel, E.; Han, S.; Garcia, S.; Pines, A.; Sen, P. N.; Song, Y. Q. Phys. Rev. Lett. 95, 075503 (2005). Copyright (2005) by the American 
Physical Society. 
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As an example, Figure 15b shows 2D RD MR images of 
HP propane, which was produced by propene hydrogenation 
with para-H2 over an Rh catalyst, flowing in a microfluidic 
capillary.[230a] Overall, the combined sensitivity gain provided by 
the RD scheme and PHIP was 48,000-fold, and the experiments 
turned out to be one to two orders of magnitude more sensitive 
than the corresponding RD experiments with HP Xe. 
Comparison of the TOF images of a gas and a liquid (Figures 
15b and 15c) nicely depicts different flow behavior of these 
phases; laminar flow of a liquid translates the encoded liquid 
molecules over a large distance (Figure 15c), whereas for a gas 
the three orders of magnitude faster diffusion causes efficient 
mixing of the flow lamellas, leading to a significantly less 
dispersed, plug-like flow behavior (Figure 15b).[230a, b] 
 
Figure 15. (a) RD MRI setup of a simplified microfluidic system consisting of a 
capillary leading through the encoding and detection coils. TOF RD MRI 
visualization of (a) HP propane and (b) water flow in the capillary (outlined in 
white), revealing much more extensive dispersion of liquid than that of gas 
molecules. TOF (ms) is shown at the bottom of the panels. The panels on the 
left are sums of the other panels.[230a] 
Experiments with model microfluidic chips have supported 
the viability of the RD-PHIP approach for visualization of 
complex microfluidic geometries and flow quantification, Figure 
16.[230a] Moreover, these experiments exposed the 
manufacturing imperfections of the chips. The gas flow in 
different channels varied in an irregular manner, and the signal 
amplitude profiles revealed an inhomogeneous distribution of the 
gas, implying that the channel depth varied from one channel to 
another. 
 
Figure 16. RD MRI of HP propane in microfluidic chips with (a) a widened 
channel in the middle part and (b) ladder-like channels (outlined in white). 
These images are the sum of the panels measured at different TOF instances, 
and they expose, e.g., manufacturing imperfections. Flow velocities extracted 
from TOF data are shown in (b). Reproduced with permission from Ref. [230a] © 
John Wiley & Sons, Ltd., 2010. 
10.2. Microfluidic reactor imaging 
The natural ability of para-H2 to participate in many important 
chemical reactions, including those performed with the use of 
microfluidic devices, opens an avenue for scientifically and 
technologically fascinating studies using HP gases. Combined 
RD MRI and PHIP methodologies in such studies was 
exemplified by the demonstration of catalytic reaction imaging of 
microscale catalyst layers.[230c] Tiny layers of heterogeneous Rh 
catalyst packed in thin capillaries (150-800 µm in diameter) 
served as model microfluidic reactors. It was shown that the RD-
PHIP methodology can be used for visualization of mass 
transport and progress of gas-phase propene hydrogenation 
reaction inside the reactors. 
The white dashed rectangles in Figure 17 highlight the 
locations of the catalyst layers. The accumulation of produced 
HP propane with the distance that gas mixture travels inside the 
catalyst layer is visualized by the increased signal amplitude in 
the lower part of the reactor. It was shown that under the given 
conditions (relatively short travel times), the signal decay due to 
nuclear spin relaxation was quite insignificant, and the amplitude 
of the HP propane signal was directly proportional to reaction 
yield, allowing the determination of the rate of propene 
hydrogenation. 
In addition, the experiments enabled the observation of 
gas adsorption effects in the microfluidic reactors during their in 
situ operation, and an elegant approach for quantifying the 
amount of absorbed gas using RD NMR was proposed. The 
authors also introduced the concept of a microfluidic nuclear 
polarizer based on their findings about PHIP produced in the 
microscale heterogeneous catalytic hydrogenation. 
 
Figure 17. RD MRI visualization of reaction progress inside a catalyst layer 
packed in a thin capillary. (a) Sample setup. 2D TOF images of HP propane 
resulting from the hydrogenation reaction in the reactors of (a) 800 and (b) 150 
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µm in diameter. The reactors are outlined by a white dashed line in the figures. 
TOF (ms) is shown at the bottom of the panels. The panels on the left are the 
sums of all other panels in each series.[230c] 
Further efforts were directed to the development of the 
concept by employing micro-engineering technologies to 
produce micro-structured lab-on-a-chip reactors with the catalyst 
(sputtered Pt) deposited on the inner surface of the channels.[231] 
It was found that these reactors did not provide PHIP. However, 
these studies provided a platform for further development of RD 
NMR for future HP applications, e.g., by using Hadamard 
encoding to achieve a better chemical resolution.[231b] 
10.3. Outcome and perspectives 
The current advances in RD MRI with HP gases already offer 
many interesting applications as highlighted above. The major 
issues concerning the methodology are related to the availability 
of HP gases and the lifetime of hyperpolarization. HP 129Xe is 
typically more expensive than the 1H HP hydrocarbon gases 
produced using PHIP. On the other hand, the nuclear spin 
relaxation causes more severe problems in the case of HP 
hydrocarbons. Recent developments in the field of long-lived 
nuclear spin states,[232] however, may alleviate the latter problem. 
For instance, it has been shown that a long-lived HP state in 
ethylene gas can survive for ca. 15 min.[233] The further RD NMR 
development could concern utilization of such extremely long-
lived HP. In addition, the progress achieved in the field of single-
scan ultra-fast NMR techniques[234] also offers new capabilities, 
which earlier were considered incompatible with NMR 
hyperpolarization. For example, recent work demonstrates the 
feasibility of single-scan 2D Laplace NMR experiments of 
dissolved HP propene,[235] and the method should be applicable, 
e.g., for the investigation of dynamics and physical environments 
of HP gases in porous media, both with high-field and low-field 
(mobile) NMR instruments.[235-236] 
11. Conclusion 
The development and applications of HP gases continue to 
advance, and show no sign of slowing down. In addition to 
SEOP hyperpolarization for production of HP 3He and 129Xe, (i) 
the SEOP HP technique has been expanded to several other 
noble gases, (ii) the heterogeneous PHIP[28a] technique has 
enabled production of HP hydrocarbons in pure form (free from 
contamination by the catalyst), and (iii) the dissolution DNP 
technique was demonstrated for production of HP 129Xe[26, 53a] 
and 15N2O gases.[237] Thus, many other gases could be 
potentially amenable to DNP hyperpolarization. 
As a result of these fundamental advances in the physics, 
chemistry and engineering of hyperpolarization processes, 
which enabled more efficient production of established HP 
gases (e.g. higher throughput and greater polarization in 129Xe 
hyperpolarizers[43i, 238]) and other advances that enabled the 
production of new HP gases, it was possible to significantly 
expand the reach of applications of HP gases in biomedicine 
and other fields. For example, as described in this mini-review, 
HP 129Xe is now being employed for in vivo thermometry, brown 
fat imaging, targeted biosensors, and many other exciting 
applications, whereas HP hydrocarbons are already used for 
high-resolution 3D imaging, remote detection, and microfluidic 
imaging. Many other new applications will likely emerge given 
that HP gases are becoming more available to researchers, 
because hyperpolarization equipment is becoming more readily 
available through commercial sources (as opposed to custom 
made in the research labs of specialists, as was generally the 
case only one decade ago). So far, physicists have been the 
main driving force behind the development of MRI of 
hyperpolarized gases. However, before their entry into routine 
clinical practice, further research is needed to improve image 
quality and validate its use, qualitatively and quantitatively, in 
respiratory disease. This will undoubtedly require collaboration 
between physicists and clinicians. Moreover, the better-
established applications (e.g. lung imaging using HP 129Xe) will 
likely continue to be more fully developed, to the point when 
studies will be driven by medical doctors (the ultimate users of 
this technology) rather than by the physicists and chemists who 
pioneered the technology and helped bring it from the proof-of-
principle stage to the clinical scale. We look forward to all of 
these developments with great excitement. 
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